Miromatrix Announces Participation in the 19th Annual Craig-Hallum Institutional Investor Conference

Rhea-AI Summary

Miromatrix Medical Inc. (NASDAQ: MIRO) announced participation in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022. This event will not feature a webcast. Miromatrix is focused on bioengineering fully transplantable organs, using its proprietary perfusion technology to address organ shortages, specifically targeting human livers and kidneys. The company aims to save and improve patients' lives through its innovative approach to organ development.

Positive

• Participation in a prominent investor conference may enhance visibility among institutional investors.
• Focus on bioengineering transplantable organs addresses a critical shortage, positioning the company as a pioneer in a growing market.

Negative

• None.

EDEN PRAIRIE, Minn., May 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that members of the management team will participate in the upcoming 19th Annual Craig-Hallum Institutional Investor Conference on June 1^st, 2022. Due to the format of this event, no webcast will be available.

About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com

Media Contact:
press@miromatrix.com

FAQ

What is Miromatrix Medical Inc. presenting at the Craig-Hallum Conference?

Miromatrix Medical Inc. will participate in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022.

Is there a webcast available for the Miromatrix conference presentation?

No, there will be no webcast available for the Miromatrix presentation at the conference.

What technology does Miromatrix focus on?

Miromatrix focuses on bioengineering fully transplantable human organs using proprietary perfusion technology.

What organs is Miromatrix primarily developing?

Miromatrix is primarily focused on developing human livers and kidneys.